stoxline Quote Chart Rank Option Currency Glossary
Ionis Pharmaceuticals, Inc. (IONS)
40.91  -0.63 (-1.52%)    04-17 16:00
Open: 41.37
High: 41.6
Volume: 1,083,335
Pre. Close: 41.54
Low: 40.76
Market Cap: 5,963(M)
Technical analysis
2024-04-17 4:47:33 PM
Short term     
Mid term     
Targets 6-month :  50.63 1-year :  52.5
Resists First :  43.34 Second :  44.95
Pivot price 42.73
Supports First :  40.75 Second :  33.91
MAs MA(5) :  41.64 MA(20) :  42.86
MA(100) :  47.57 MA(250) :  44.07
MACD MACD :  -0.9 Signal :  -0.8
%K %D K(14,3) :  6.3 D(3) :  8.1
RSI RSI(14): 34.7
52-week High :  54.43 Low :  34.31
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IONS ] has closed above bottom band by 3.5%. Bollinger Bands are 15.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 41.87 - 42.27 42.27 - 42.52
Low: 39.9 - 40.43 40.43 - 40.75
Close: 40.31 - 41.16 41.16 - 41.68
Company Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Headline News

Tue, 16 Apr 2024
24,243 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Purchased by HealthInvest Partners AB - MarketBeat

Sun, 14 Apr 2024
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S - Simply Wall St

Sat, 13 Apr 2024
Arizona State Retirement System Has $1.82 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Fri, 29 Mar 2024
Ionis to hold olezarsen Phase 3 data webcast - BioSpace

Sat, 24 Feb 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Yearly Results And Analysts Are Updating Their Estimates - Yahoo Finance

Thu, 22 Feb 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 146 (M)
Shares Float 145 (M)
Held by Insiders 0.8 (%)
Held by Institutions 100.9 (%)
Shares Short 9,520 (K)
Shares Short P.Month 9,110 (K)
Stock Financials
EPS -2.56
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.68
Profit Margin -46.5 %
Operating Margin 4.7 %
Return on Assets (ttm) -7.6 %
Return on Equity (ttm) -76.4 %
Qtrly Rev. Growth 113.5 %
Gross Profit (p.s.) 0
Sales Per Share 5.4
EBITDA (p.s.) -2.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -308 (M)
Levered Free Cash Flow -160 (M)
Stock Valuations
PE Ratio -15.99
PEG Ratio 0.2
Price to Book value 15.26
Price to Sales 7.57
Price to Cash Flow -19.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android